Shares of Compugen Ltd. (NASDAQ:CGEN) shot up 3.8% on Thursday . The company traded as high as $6.94 and last traded at $6.91, with a volume of 66,127 shares. The stock had previously closed at $6.66.

A number of brokerages have recently weighed in on CGEN. FBR & Co restated a “buy” rating on shares of Compugen in a research note on Thursday, May 12th. Zacks Investment Research cut shares of Compugen from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $10.25.

The company’s 50-day moving average is $6.69 and its 200-day moving average is $6.23. The company’s market capitalization is $352.28 million.

Compugen (NASDAQ:CGEN) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. On average, equities analysts predict that Compugen Ltd. will post ($0.56) earnings per share for the current year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.